Zentalis Pharmaceuticals Stock (NASDAQ:ZNTL)
Previous Close
$2.99
52W Range
$2.66 - $18.07
50D Avg
$3.42
200D Avg
$7.86
Market Cap
$223.06M
Avg Vol (3M)
$2.07M
Beta
1.74
Div Yield
-
ZNTL Company Profile
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
ZNTL Performance
Peer Comparison
Ticker | Company |
---|---|
GRCL | Gracell Biotechnologies Inc. |
OLMA | Olema Pharmaceuticals, Inc. |
SANA | Sana Biotechnology, Inc. |
KYMR | Kymera Therapeutics, Inc. |
CGEM | Cullinan Oncology, Inc. |
VECT | VectivBio Holding AG |
RVMD | Revolution Medicines, Inc. Warrant |
BPMC | Blueprint Medicines Corporation |
DAWN | Day One Biopharmaceuticals, Inc. |
ERAS | Erasca, Inc. |
SNDX | Syndax Pharmaceuticals, Inc. |
INZY | Inozyme Pharma, Inc. |
ANNX | Annexon, Inc. |
GLUE | Monte Rosa Therapeutics, Inc. |
DSGN | Design Therapeutics, Inc. |
ITOS | iTeos Therapeutics, Inc. |
PTGX | Protagonist Therapeutics, Inc. |
LIFE | aTyr Pharma, Inc. |